Resolvin D5 (RvD5) is a D-series resolvin synthesized from DHA (docosahexaenoic acid) during the active resolution phase of acute inflammation. As a member of the Specialized pro-resolving mediators (SPMs) family, RvD5 binds to specific G-protein coupled receptors to halt neutrophil infiltration, promote Efferocytosis, dampen pro-inflammatory cytokine production, and accelerate tissue regeneration. It represents the body's endogenous "off switch" for inflammation, transforming an inflammatory environment into a pro-healing one.
Imagine a construction site where a building caught fire. The fire department (pro-inflammatory phase) arrived, smashed windows, flooded the place with water, and created necessary chaos to stop the flames. Now the fire is out, but the site is a wreck—broken glass everywhere, water pooling, debris scattered. RvD5 is like the foreman who arrives at dawn with a specific set of instructions: "Stop bringing more fire trucks. Start clearing the debris. Begin repairing windows. Send the injured workers to medical care."
The foreman doesn't just yell "clean up"—he has specific walkie-talkie channels (GPCRs) to communicate with different teams. He tells the demolition crew (neutrophils) to stop smashing things and go home. He directs the cleanup crew (macrophages) to switch from "destroy" mode to "repair" mode, picking up broken materials (apoptotic cells) without triggering more alarms. He radios the supply chain to stop sending pro-inflammatory materials (IL-1β, TNF-α) and start delivering building materials (growth factors, anti-inflammatory signals). The whole site transitions from "emergency response" to "reconstruction"—and RvD5 is the specific signal molecule that orchestrates this shift. Without enough RvD5 (because you're low on DHA, the raw material), the site stays in chaos mode: fire trucks keep arriving, debris piles up, and the building never gets repaired. That's chronic low-grade inflammation.
RvD5 biosynthesis occurs during Lipid mediator class switching, when the inflammatory environment (high IL-1β, TNF-α, oxidative stress) triggers enzymatic conversion of DHA stored in cell membranes:
- Release of DHA: Phospholipase A2 (PLA2G7) liberates DHA from membrane phospholipids during inflammatory activation
- Enzymatic conversion: 15-LOX (15-lipoxygenase) converts DHA → 17S-hydroxy-DHA intermediate → 7,17-dihydroxy-4Z,8E,10Z,13Z,15E,19Z-docosahexaenoic acid (RvD5)
- Receptor binding: RvD5 binds to GPR101 (orphan GPCR, primary receptor for D-series resolvins) and potentially GPR32 (also binds RvD1, RvD3)
- Downstream signaling cascade:
graph TD
A[RvD5] --> B[GPR101 / GPR32]
B --> C["Gαi activation"]
C --> D["↓ cAMP"]
C --> E["↑ ERK1/2 phosphorylation"]
D --> F["↓ PKA activity"]
F --> G["↓ NF-κB nuclear translocation"]
G --> H["↓ Pro-inflammatory gene transcription"]
H --> I["↓ IL-1β, TNF-α, IL-6"]
E --> J["↑ Anti-inflammatory signaling"]
J --> K["↑ Efferocytosis machinery"]
J --> L["↑ M2 macrophage polarization"]
B --> M["β-arrestin recruitment"]
M --> N[Receptor internalization]
N --> O[Signal termination]
-
Cellular effects:
- Neutrophil arrest: RvD5 inhibits neutrophil transendothelial migration by downregulating CD62L (L-selectin) surface expression and blocking CXCR3-mediated chemotaxis toward CXCL1 gradients
- Macrophage reprogramming: Shifts macrophages from M1 (pro-inflammatory, IL-12, TNF-α producers) to M2 macrophages (anti-inflammatory, IL-10, TGF-beta producers) via PPARα activation
- Efferocytosis enhancement: Upregulates surface receptors for phosphatidylserine recognition (e.g., MerTK, TIM-4) on macrophages, increasing apoptotic cell clearance rate by ~300% in vitro
- Pain reduction: Inhibits TRPV1 and TRPA1 activation on sensory neurons, reducing nociceptive signaling
- Tissue regeneration: Stimulates fibroblast proliferation and collagen deposition while limiting excessive fibrosis via TGF-beta modulation
-
Metabolic inactivation: RvD5 is enzymatically degraded by eicosanoid oxidoreductase and dehydrogenases, limiting its action to picogram concentrations (EC50 ~0.1-1 nM) and short half-life (~minutes in circulation, hours in tissue)
RvD5 is a key therapeutic target in cPNI because it represents the execution phase of resolution—the actual molecular machinery that terminates inflammation. Deficiency or dysfunction in RvD5 production explains why many patients with adequate Omega-3 intake still exhibit chronic low-grade inflammation: they may lack the enzymatic capacity (15-LOX polymorphisms, oxidative enzyme damage) or the signaling machinery (receptor downregulation, receptor resistance) to synthesize or respond to SPMs.
Relevant patient populations:
Metamodel connections:
- Selfish Immune System: When resolution fails, the immune system prioritizes survival (maintaining inflammatory readiness) over repair, leading to collateral tissue damage—RvD5 realigns immune behavior toward host benefit
- Evolutionary mismatch: Modern Omega-3 deficiency (Western diet low in DHA, high in linoleic acid) means insufficient substrate for RvD5 synthesis. Hunter-gatherers consuming fish, shellfish, and wild game had ~10x higher Omega-3 intake
- Lipid mediator class switching (Module 5 core concept): RvD5 synthesis represents the critical transition from COX-2/5-LOX-derived pro-inflammatory eicosanoids (PGE2, LTB4) to 15-LOX-derived pro-resolving mediators
Clinical thresholds:
- Plasma DHA levels: <4% of total fatty acids correlates with impaired SPM synthesis (optimal >8%)
- Resolution interval Resolution interval (R_i): Prolonged Ri (>72 hours in acute models) suggests SPM deficiency
- Pain VAS reduction: Exogenous RvD5 (or SPM precursors) can reduce pain scores by 30-50% in inflammatory pain models within 24-48 hours
Intervention implications:
- Substrate provision: Ensure adequate DHA (2-4g/day from EPA/DHA combined) but recognize this is necessary, not sufficient
- Enzyme co-factors: Support 15-LOX activity with adequate selenium (Selenium, 200 mcg/day), Vitamin E (mixed tocopherols, not just α-tocopherol which can inhibit γ-tocopherol's anti-inflammatory effects)
- Reduce SPM degradation: Limit alcohol (upregulates eicosanoid oxidoreductase), control hyperglycemia (glycates SPM receptors)
- Lifestyle SPM enhancers: Exercise acutely increases 15-LOX expression; intermittent fasting upregulates SPM receptor sensitivity
- Consider exogenous SPMs: Emerging therapies include purified RvD5 or synthetic analogs (AT-RvD5) for refractory inflammatory conditions
- RvD5 is synthesized from DHA by 15-LOX during the resolution phase (typically 12-48 hours post-inflammatory peak)
- Primary receptor: GPR101 (also GPR32); signals via Gαi → ↓cAMP → ↓NF-κB → ↓pro-inflammatory cytokines
- Effective concentration: picomolar to low nanomolar range (EC50 ~0.1-1 nM for neutrophil inhibition)
- RvD5 reduces neutrophil infiltration by ~60-80% in murine peritonitis models when administered at inflammatory peak
- Enhances Efferocytosis rate by ~3-fold via upregulation of MerTK and TIM-4 receptors on macrophages
- Half-life: Minutes in circulation, hours in inflamed tissue (protected from degradation by albumin binding)
- Clinical deficit marker: Resolution interval (R_i) >72 hours (normal ~24-48 hours) suggests SPM insufficiency
- RvD5 levels are 50-70% lower in synovial fluid of Rheumatoid arthritis patients vs. osteoarthritis controls
- Aspirin enhances D-series resolvin production via COX-2 acetylation (Aspirin-triggered resolvins), but does not directly increase RvD5 (primarily affects E-series and AT-RvD pathways)
- Evolutionary context: RvD5 synthesis requires DHA, which humans cannot synthesize de novo due to loss of Δ4-desaturase—obligate dietary requirement
- Specialized pro-resolving mediators (SPMs) — RvD5 is a member of this broader family of endogenous resolution mediators
- Resolvins — specific subfamily of SPMs; RvD5 belongs to the D-series (DHA-derived) resolvins
- DHA — obligate precursor substrate; RvD5 synthesis requires membrane DHA stores released by phospholipase A2
- Lipid mediator class switching — RvD5 production exemplifies the enzymatic switch from pro-inflammatory (COX/5-LOX) to pro-resolving (15-LOX) pathways
- Efferocytosis — RvD5 upregulates macrophage clearance of apoptotic neutrophils, preventing secondary necrosis and perpetuation of inflammation
- Resolution interval (R_i) — RvD5 administration shortens Ri by accelerating neutrophil apoptosis and clearance
- 15-LOX — key biosynthetic enzyme converting DHA → 17S-hydroxy-DHA → RvD5
- Neutrophil — primary cellular target; RvD5 halts transendothelial migration and promotes apoptosis
- M2 macrophages — RvD5 promotes M1→M2 polarization via PPARα activation and IL-10 production
- Chronic low-grade inflammation — RvD5 deficiency (due to inadequate DHA, enzyme dysfunction, or receptor resistance) perpetuates failed resolution
- Omega-3 — RvD5 is one molecular mechanism explaining anti-inflammatory effects of omega-3 supplementation
- COX-2 — RvD5 production represents the resolution phase after COX-2-driven PGE2 peaks; aspirin-acetylated COX-2 can enhance some SPMs but not RvD5 directly
- Rheumatoid arthritis — synovial fluid RvD5 levels inversely correlate with disease activity; therapeutic target for failed resolution
- Type 2 Diabetes — adipose tissue inflammation involves impaired RvD5 synthesis; metaformin may partially restore SPM production
- TRPV1 — RvD5 inhibits TRPV1 activation on sensory neurons, reducing inflammatory pain without opioid receptor involvement
- NF-κB — RvD5 suppresses NF-κB nuclear translocation, reducing transcription of IL-1β, TNF-α, COX-2 genes
- IL-10 — RvD5 stimulates IL-10 secretion from macrophages, creating an anti-inflammatory cytokine milieu
- Acute inflammation — RvD5 is synthesized during the self-resolving phase of acute inflammation; absence leads to chronicity
- Inflammatory resolution — RvD5 is a molecular executor of the resolution program, distinct from passive decay of inflammation
- Maresins — parallel SPM family also derived from DHA via 12-LOX pathway; work synergistically with resolvins
- Protectins — another DHA-derived SPM family (e.g., neuroprotectin D1); share overlapping but distinct receptor targets with RvD5
- RvD1 — closely related D-series resolvin with similar but non-redundant functions; both signal via GPR32 but have distinct receptor profiles
- EPA — precursor to E-series resolvins; while structurally different from RvD5, EPA-derived SPMs (RvE1-3) complement RvD5 actions in resolution
- Exercise — acute exercise increases 15-LOX expression and circulating SPM levels, including RvD5